EarningsThe company's second-quarter sales exceeded expectations by 8%, driven by strong performance in the iDose segment.
Market OpportunityKeratoconus impacts about 600,000 people annually, representing a significant market opportunity for GKOS estimated at approximately $3 billion.
Product PreferenceSurvey results show a clear preference for Epi-On over Epi-Off, with a 61% to 39% split, indicating positive market sentiment towards Epioxa.